Literature DB >> 19860723

Origins, controversies and recent developments of the MCI construct.

G Gainotti1.   

Abstract

The MCI construct aims to investigate the grey area existing between normal aging and dementia, in order to identify it in the preclinical stage patients at risk of developing dementia. The construct of the MCI has been proposed by taking the neuropathological staging of the Alzheimer's disease (AD) as reference and providing an explicit set of identifying criteria, but it has raised two main problems: (a) the variability of estimates concerning the actual rate of conversion from MCI to dementia, and (b) the number of subjects who return to normality. These problems stem in part from the operational difficulties met by the MCI identifying criteria concerned with: the memory tests used, the cut-off adopted to identify patients with an 'objective' memory disorder, the assessment of subjective memory disorders, and the integrity of daily living activities. After a short discussion of these operational difficulties, I will pass to shortly survey the laboratory data providing additional predictive value for the conversion of MCI to dementia (ApoE4, CSF biomarkers, Neuroimaging data, and Vascular risk factors) and some recent attempts to identify pre-MCI patients, with a purely subjective cognitive impairment. I will conclude my review by asking if we have a single MCI or a family of MCI constructs, each of whom could play a preferential role in specific clinical contexts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19860723     DOI: 10.2174/156720510791050858

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  6 in total

1.  Position paper of the Italian Society for the study of Dementias (SINDEM) on the proposal of a new lexicon on Alzheimer disease.

Authors:  Massimo Musicco; Alessandro Padovani; Sandro Sorbi; Elio Scarpini; Paolo Caffarra; Stefano Cappa; Francesca Clerici; Massimo Tabaton; Carlo Caltagirone; Vincenzo Bonavita; Amalia C Bruni; Giuseppe Bruno; Antonio Federico; Carlo Ferrarese; Camillo Marra; Benedetta Nacmias; Lucilla Parnetti; Carla Pettenati; Giuseppe Sorrentino; Fabrizio Tagliavini; Claudio Mariani
Journal:  Neurol Sci       Date:  2011-11-05       Impact factor: 3.307

2.  [Prediction Models of Mild Cognitive Impairment Using the Korea Longitudinal Study of Ageing].

Authors:  Hyojin Park; Juyoung Ha
Journal:  J Korean Acad Nurs       Date:  2020-04       Impact factor: 0.984

3.  Help-seeking preferences in the area of mild cognitive impairment: comparing family physicians and the lay public.

Authors:  Perla Werner; Jeremia Heinik; Shmuel Giveon; Dikla Segel-Karpas; Eliezer Kitai
Journal:  Clin Interv Aging       Date:  2014-04-09       Impact factor: 4.458

4.  Age-correction of test scores reduces the validity of mild cognitive impairment in predicting progression to dementia.

Authors:  Johannes Hessler; Oliver Tucha; Hans Förstl; Edelgard Mösch; Horst Bickel
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

5.  Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.

Authors:  A Lacour; A Espinosa; E Louwersheimer; S Heilmann; I Hernández; S Wolfsgruber; V Fernández; H Wagner; M Rosende-Roca; A Mauleón; S Moreno-Grau; L Vargas; Y A L Pijnenburg; T Koene; O Rodríguez-Gómez; G Ortega; S Ruiz; H Holstege; O Sotolongo-Grau; J Kornhuber; O Peters; L Frölich; M Hüll; E Rüther; J Wiltfang; M Scherer; S Riedel-Heller; M Alegret; M M Nöthen; P Scheltens; M Wagner; L Tárraga; F Jessen; M Boada; W Maier; W M van der Flier; T Becker; A Ramirez; A Ruiz
Journal:  Mol Psychiatry       Date:  2016-03-15       Impact factor: 15.992

6.  Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study.

Authors:  Isaac Acosta; Guilherme Borges; Rebeca Aguirre-Hernandez; Ana Luisa Sosa; Martin Prince
Journal:  Alzheimers Dement       Date:  2017-10-10       Impact factor: 21.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.